Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives.
暂无分享,去创建一个
A. Marchetti | F. Buttitta | P. Radice | P. Tassone | P. Tagliaferri | A. Sapino | N. Normanno | S. Pignata | M. Genuardi | E. Ricevuto | P. Marchetti | A. Russo | B. Pasini | N. Colombo | M. Gion | L. Cortesi | P. Carrera | C. Trevisiol | L. Varesco | E. Capoluongo | M. Bella | S. Gori | M. Truini | V. Guarneri | D. Lorusso | M. Barberis | M. Pensabene | L. Incorvaia | N. La Verde
[1] P. Tassone,et al. The Era of PARP inhibitors in ovarian cancer: "Class Action" or not? A systematic review and meta-analysis. , 2018, Critical reviews in oncology/hematology.
[2] A. Toss,et al. PARP Inhibitors for the Treatment of Ovarian Cancer. , 2018, Current cancer drug targets.
[3] A. Oza,et al. Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] A. Oza,et al. Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] Karl Kashofer,et al. Multi-laboratory proficiency testing of clinical cancer genomic profiling by next-generation sequencing. , 2018, Pathology, research and practice.
[6] F. Mignone,et al. A comprehensive BRCA1/2 NGS pipeline for an immediate Copy Number Variation (CNV) detection in breast and ovarian cancer molecular diagnosis. , 2018, Clinica chimica acta; international journal of clinical chemistry.
[7] G. Scambia,et al. A Whole Germline BRCA2 Gene Deletion: How to Learn from CNV In Silico Analysis , 2018, International journal of molecular sciences.
[8] Miika Ahdesmäki,et al. An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practice , 2017, Human mutation.
[9] V. Gebski,et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. , 2017, The Lancet. Oncology.
[10] P. Schirmacher,et al. Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients. , 2017, Seminars in oncology.
[11] Juanita Lopez,et al. Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials. , 2017, European journal of cancer.
[12] B. Arun,et al. BRCA mutation genetic testing implications in the United States. , 2017, Breast.
[13] B. Monk,et al. Trabectedin as a chemotherapy option for patients with BRCA deficiency. , 2016, Cancer treatment reviews.
[14] Ignace Vergote,et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. , 2016, The New England journal of medicine.
[15] A. Marchetti,et al. Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients. , 2016, Future oncology.
[16] A. Bryant,et al. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. , 2015, The Cochrane database of systematic reviews.
[17] H. Rehm,et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.
[18] D. Matei,et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial , 2014 .
[19] J. Jonkers,et al. Opportunities and hurdles in the treatment of BRCA1-related breast cancer , 2014, Oncogene.
[20] D. Matei,et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. , 2014, The Lancet. Oncology.
[21] Borut Peterlin,et al. Recommendations for reporting results of diagnostic genetic testing (biochemical, cytogenetic and molecular genetic) , 2013, European Journal of Human Genetics.
[22] J. George,et al. Nonequivalent Gene Expression and Copy Number Alterations in High-Grade Serous Ovarian Cancers with BRCA1 and BRCA2 Mutations , 2013, Clinical Cancer Research.
[23] Nicola J. Curtin,et al. DNA repair dysregulation from cancer driver to therapeutic target , 2012, Nature Reviews Cancer.
[24] J. George,et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Douglas F. Easton,et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. , 2012, JAMA.
[26] A. Gabizon,et al. BRCA Mutation Status and Determinant of Outcome in Women with Recurrent Epithelial Ovarian Cancer Treated with Pegylated Liposomal Doxorubicin , 2011, Molecular Cancer Therapeutics.
[27] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[28] A. Spurdle,et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results , 2008, Human mutation.
[29] I. Jacobs,et al. BRCA1 and BRCA2 Mutation Prevalence and Clinical Characteristics of a Population-Based Series of Ovarian Cancer Cases from Denmark , 2008, Clinical Cancer Research.
[30] R. Buller,et al. Inactivation of BRCA1 and BRCA2 in ovarian cancer. , 2002, Journal of the National Cancer Institute.
[31] A. Devereau,et al. Practice Guidelines for the Evaluation of Pathogenicity and the Reporting of Sequence Variants in Clinical Molecular Genetics . , 2013 .